Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by TheMadMonkon Apr 08, 2022 6:14pm
227 Views
Post# 34589494

RE:Need Some Good News

RE:Need Some Good News
Dusty,
 
It does not matter if the price is 80 cents, 50 cents, or $1.80.  This is not the type of stock you should be trading for a profit of a few pennies; the volume and market cap are way too low.  One investor moving in or one investor moving out can cause huge swings in the price in either direction.  If you want to trade buy Google or an oil stock on a dip and turn around and flip it for a small profit (IMO).  This is a "Swing for the Fences" kind of stock, you are going to hit a homerun or go down swinging.  If just one of their drugs get approved by the FDA you have a company that is worth over a billion dollars, if not you will be diluted into the abyss.  If you believe in the science, buy what you can afford to loose and put it away for a couple of years.  Personally, I look at it as an end of 2025 or spring of 2026 story, hopefully I will be retiring then.  If you watch every penny up and down, you probably won't survive until 2025 or 2026.  I kind of hope that we get back below 70 cents so I can buy some more, not that I need any more but below 70, I have a hard time resisting.  Just my opinion which is only worth what you paid for it.
<< Previous
Bullboard Posts
Next >>